Aurobindo Pharma Ltd 2017 AR2
The report highlights Aurobindo Pharma Limited's financial and operational performance for the fiscal year 2016-17, achieving a consolidated revenue of INR 150,899 million, representing an 8.1% growth. The company expanded its global footprint through key acquisitions, including Generis Farmacêutica S.A. in Portugal and product rights in France. Aurobindo advanced its complex product pipeline by entering the biosimilars market with the acquisition of five molecules and expanding its oncology, dermatology, and vaccine development. Additionally, the company prioritized environmental sustainability by re-engineering storm water drainage systems and achieving ISO 14001 accreditation for its largest API manufacturing unit.
Company: Aurobindo Pharma Ltd
Sector: Manufacturing
Country: India
Year: 2017
Type: AR2
Pages: 228
Back to company
Aurobindo Pharma Ltd
Annual Report
The report highlights Aurobindo Pharma Limited's financial and operational performance for the fiscal year 2016-17, achieving a consolidated revenue of INR 150,899 million, representing an 8.1% growth. The company expanded its global footprint through key acquisitions, including Generis Farmacêutica S.A. in Portugal and product rights in France. Aurobindo advanced its complex product pipeline by entering the biosimilars market with the acquisition of five molecules and expanding its oncology, dermatology, and vaccine development. Additionally, the company prioritized environmental sustainability by re-engineering storm water drainage systems and achieving ISO 14001 accreditation for its largest API manufacturing unit.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees